Compass Therapeutics Inc. (CMPX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
CMPX Chart
Compass Therapeutics Inc. (CMPX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Compass Therapeutics Inc. ever had a stock split?
Compass Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Thomas J. Schuetz M.D., Ph.D. CEO | NASDAQ (CM) Exchange | US20454B1044 ISIN |
| United States Country | 32 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a clear focus on oncology, dedicating its efforts to crafting antibody-based therapeutics intended for the treatment of a wide array of human diseases. Established in the United States in 2014, the company has made significant strides in the healthcare and pharmaceutical landscape. Headquartered in Boston, Massachusetts, Compass Therapeutics stands out for its innovative approach to tackling cancer, leveraging cutting-edge scientific research to develop treatments that aim to improve the lives of patients grappling with this challenging disease.
Products and Services
- CTX-009
- CTX-471
- CTX-8371
This bispecific antibody represents a significant advancement in cancer treatment, targeting and blocking two critical pathways: Delta-like ligand 4 (a ligand of Notch-1) and vascular endothelial growth factor A (VEGFA). These pathways play essential roles in angiogenesis and tumor vascularization, processes that are vital for tumor growth and survival. By inhibiting these pathways, CTX-009 aims to hinder tumor progression and support the body's fight against cancer.
An agonistic monoclonal antibody of the IgG4 subtype, CTX-471 stimulates CD137, a crucial co-stimulatory receptor found on immune cells. CD137 is known for its role in enhancing the immune system's ability to fight cancer. Through its activation, CTX-471 seeks to bolster the body's natural defenses against tumor cells, offering a promising approach to cancer immunotherapy by empowering the immune response against the disease.
As a bispecific inhibitor, CTX-8371 is designed to target and inhibit the interaction between PD-1 and PD-L1. These proteins are often exploited by cancer cells to evade the immune system. By disrupting this interaction, CTX-8371 intends to lift the veil of protection that tumors use to shield themselves from immune detection, thereby enhancing the body's capacity to attack and eradicate cancer cells. This innovative approach represents a frontier in the development of checkpoint inhibitor antibodies, offering hope for more effective cancer treatments.
Contact Information
